Eli Lilly and Company (NYSE:LLY) is Shufro Rose & Co. LLC's 9th Largest Position

Shufro Rose & Co. LLC cut its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,714 shares of the company's stock after selling 2,037 shares during the period. Eli Lilly and Company makes up 2.7% of Shufro Rose & Co. LLC's holdings, making the stock its 9th biggest holding. Shufro Rose & Co. LLC's holdings in Eli Lilly and Company were worth $35,291,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of LLY. Norges Bank acquired a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $8,407,908,000. Proficio Capital Partners LLC increased its position in shares of Eli Lilly and Company by 100,387.1% during the fourth quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock valued at $4,016,110,000 after acquiring an additional 5,197,038 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Eli Lilly and Company by 19.0% during the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after acquiring an additional 2,012,129 shares during the last quarter. Capital International Investors increased its position in shares of Eli Lilly and Company by 23.2% during the fourth quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after acquiring an additional 1,645,222 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $1,240,653,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.13% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on LLY shares. UBS Group dropped their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Guggenheim restated a "buy" rating on shares of Eli Lilly and Company in a report on Friday, May 23rd. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective for the company. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Finally, HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price target for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $1,011.37.

Eli Lilly and Company Stock Down 0.9%

Shares of Eli Lilly and Company stock traded down $6.63 during trading hours on Wednesday, hitting $718.59. The company had a trading volume of 2,937,655 shares, compared to its average volume of 3,620,354. The company's 50-day moving average is $784.45 and its two-hundred day moving average is $801.86. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The company has a market cap of $681.03 billion, a P/E ratio of 61.37, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same quarter in the previous year, the company posted $2.58 EPS. The company's quarterly revenue was up 45.2% on a year-over-year basis. Analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.83%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company's payout ratio is 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.